#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis


In an individual participant data meta-analysis, Caroline Crowther and colleagues examine the evidence for the neuroprotective benefits of antenatal magnesium sulphate for babies.


Vyšlo v časopise: Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med 14(10): e32767. doi:10.1371/journal.pmed.1002398
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002398

Souhrn

In an individual participant data meta-analysis, Caroline Crowther and colleagues examine the evidence for the neuroprotective benefits of antenatal magnesium sulphate for babies.


Zdroje

1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379(9832):2162–72. doi: 10.1016/S0140-6736(12)60820-4 22682464

2. Chow SSW, Le Marsney R, Hossain S, Haslam R, Lui K. 2015. Report of the Australian and New Zealand Neonatal Network 2013. Sydney.

3. World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. Geneva: WHO 2015.

4. Saigal S, Doyle LW: An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet 2008;371(9608):261–269. doi: 10.1016/S0140-6736(08)60136-1 18207020

5. Blencowe H, Lee AC, Cousens S, Bahalim A, Narwal R, Zhong N, et al. Preterm birth-associated neurodevelopmental impairment estimates at regional and global levels for 2010. Pediatr Res 2013; 74(Suppl 1):17–34.

6. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197–223. doi: 10.1016/S0140-6736(12)61689-4 23245608

7. Kuban KCK, Leviton A, Pagano M, Fenton T, Strassfeld R, Wolff M. Maternal toxemia is associated with reduced incidence of germinal matrix hemorrhage in premature babies. J Child Neurol 1992;7(1):70–6. doi: 10.1177/088307389200700113 1552156

8. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995;95(2):263–9. 7838646

9. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003;290(20):2669–76. doi: 10.1001/jama.290.20.2669 14645308

10. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, et al. PREMAG trial group Magnesium sulphate given before very-preterm birth to protect infant brain: the randomized controlled PREMAG trial. BJOG. 2007;114:310–8.

11. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. Am J Obstet Gynecol 2002;186(6):1111–8. 12066082

12. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359(9321):1877–90. 12057549

13. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359(9):895–905. doi: 10.1056/NEJMoa0801187 18753646

14. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009;1:CD004661.

15. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal Magnesium Sulphate Prior to Preterm Birth for Neuroprotection of the Fetus, Infant and Child: National Clinical Practice Guidelines. Adelaide: The University of Adelaide, 2010.

16. Magee L, Sawchuck D, Synnes A, von Dadelszen P. Magnesium Sulphate for Fetal Neuroprotection Consensus Committee. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynaecol Can 2011;33(5):516–29. 21639972

17. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002,25(1):76–97. doi: 10.1177/0163278702025001006 11868447

18. Higgins J, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011.

19. Tierney JF, Vale C, Riley R, Smith CT, Stewart L, Clarke M, et al. Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use. PLoS Med 2015:12(7): e1001855. doi: 10.1371/journal.pmed.1001855 26196287

20. The AMICABLE Group. Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE). Systematic Reviews 2012;1:21 doi: 10.1186/2046-4053-1-21 22587882

21. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA;2015 Apr 28;313(16):1657–65. doi: 10.1001/jama.2015.3656 25919529

22. The Editorial Team. Cochrane Pregnancy and Childbirth Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016, Issue 8. Art No.: PREG.

23. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343 https://doi.org/10.1136/bmj.d5928.

24. Wolf HT, Hegaard HK, Pinborg AB, Huusom LD. Does antenatal administration of magnesium sulphate prevent cerebral palsy and mortality in preterm infants? A study protocol. AIMS Public Health 2015;2:727–9.

25. Crowther CA, Middleton PM, Wilkinson D, Ashwood P, Haslam R. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)- study protocol. BMC Pregnancy Childbirth 2013 Apr 9;13:91. doi: 10.1186/1471-2393-13-91 23570677

26. Bain ES, Middleton PF, Crowther CA. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review. BMC Pregnancy and Childbirth 2013 13:195. doi: 10.1186/1471-2393-13-195 24139447

27. Simpson KR, Knox GE: Obstetrical accidents involving intravenous magnesium sulfate: recommendations to promote patient safety. MCN Am J Matern Child Nurs. 2004,29 (3):161–169. 15123972

28. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 2010; 115(3): 669–71. 20177305

29. Peebles DM, Kenyon AP. Magnesium sulphate to prevent cerebral palsy following preterm birth. RCOG Scientific Impact Paper No. 29 August 2011.

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2017 Číslo 10
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#